Abstract:High mobility group B1 (HMGB1) is an architectural protein that recognizes the DNA damage sites formed by the platinum anticancer drugs. However, the impact of HMGB1 binding on the structural alterations of the platinum drug-treated single dsDNA molecules has remained largely unknown. Herein, the structural alterations induced by the platinum drugs, the mononuclear cisplatin and it's analog the trinuclear BBR3464, have been probed in presence of HMGB1, by atomic force microscopy (AFM) and AFM-based force spectroscopy. It is observed that the drug-induced DNA loop formation enhanced upon HMGB1 binding, most likely as a result of HMGB1-induced increase in DNA conformational flexibility that allowed the drug-binding sites to come close and form double adducts, thereby resulting in enhanced loop formation via inter-helix cross-linking. Since HMGB1 enhances DNA flexibility, the near-reversible structural transitions as observed in the force-extension curves (for 1 h drug treatment), generally occurred at lower forces in presence of HMGB1. The DNA structural integrity was largely lost after 24 h drug treatment as no reversible transition could be observed. The Young's modulus of the dsDNA molecules, as estimated from the force-extension analysis, increased upon drug treatment, due to formation of the drug-induced covalent cross-links and consequent reduction in DNA flexibility. The Young's modulus increased further in presence of HMGB1 due to HMGB1-induced enhancement in DNA flexibility that could ease formation of the drug-induced covalent cross-links. To our knowledge, this is the first report that shows an increase in the stiffness of the platinum drug-treated DNA molecules in presence of HMGB1.

Click Chemistry-Based Force Spectroscopy Revealed Enhanced Binding Dynamics of Phosphorylated HMGB1 to Cisplatin-DNA

Hmgb1 Bound To Cisplatin-Dna Adducts Undergoes Extensive Acetylation And Phosphorylation In Vivo

Clickable Cisplatin Derivatives as Versatile Tools to Probe the DNA Damage Response to Chemotherapy

Proteomic Analysis of Cisplatin- and Oxaliplatin-Induced Phosphorylation in Proteins Bound to Pt-DNA Adducts.

Proteomic Strategy for Identification of Proteins Responding to Cisplatin-Damaged DNA.

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

Simultaneous mass spectrometry analysis of cisplatin with oligonucleotide-peptide mixtures: implications for the mechanism of action

Mass Spectrometric Proteomics Reveals That Nuclear Protein Positive Cofactor PC4 Selectively Binds to Cross-Linked DNA by a Trans-Platinum Anticancer Complex

Nuclear proteome analysis of cisplatin-treated HeLa cells

Structure and Mechanism of Human DNA Polymerase Η

Base-Resolution Analysis of Cisplatin-Dna Adducts at the Genome Scale

Study on the Interactions Between Cisplatin and Cadherin by Fluorescence Spectrometry and Atomic Force Microscopy.

Binding Stability of a Cross-Linked Drug: Calculation of an Anticancer Drug Cisplatin-Dna Complex

Molecular Dynamics Studies of Changes in the DNA- Structure as Result of Interactions with Cisplatin

The role of carrier ligands of platinum(II) anticancer complexes in the protein recognition of Pt–DNA adducts

Structural characterization and DNA interactions of new cytotoxic transplatin analogues containing one planar and one nonplanar heterocyclic amine ligand

Impact of HMGB1 binding on the structural alterations of platinum drug-treated single dsDNA molecule

Nanopore Sequencing Accurately Identifies the Cisplatin Adduct on DNA.

Structural changes of linear DNA molecules induced by cisplatin.

Study on the interactions between cisplatin and cadherin

Nucleic Acid‐based Electrochemical Sensors Facilitate the Study of DNA Binding by Platinum (II)‐based Antineoplastics